Current status and future prospects for biologic treatments of psoriasis

References

• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. Epub 2009 Jul 31. doi:10.1056/NEJMra0804595. PubMed PMID: 19641206.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826–850. Epub 2008 Apr 22. doi:10.1016/j.jaad.2008.02.039. PubMed PMID: 18423260.
   PubMed Web of Science ®Google Scholar
• Sugiyama H, McCormick TS, Cooper KD, et al. Alefacept in the treatment of psoriasis. Clin Dermatol. 2008;26(5):503–508. Epub 2008 Aug 30. doi:10.1016/j.clindermatol.2007.10.028. PubMed PMID: 18755368.
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009;10(8):816–824. Epub 2009 Aug 4. doi:10.1016/s1470-2045(09)70161-5. PubMed PMID: 19647202.
   PubMed Web of Science ®Google Scholar
• Seminara N, Gelfand JM Assessing long term drug safety: lessons (re) learned from raptiva. Semin Cutan Med Surg. 2010;29(1):16–19. doi:10.1016/j.sder.2010.01.001. PubMed PMID: PMC2864916.
   PubMed Web of Science ®Google Scholar
• U.S Food and Drug Administration. FDA statement on the voluntary withdrawal of Raptiva from the U.S. Market 2009. Silver Spring (MD): U.S. Food and Drug Administration; 2016.
   Google Scholar
• Nast A, Sporbeck B, Rosumeck S, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action. J Invest Dermatol. 2013;133(8):1963–1970. Epub 2013 Feb 22. doi:10.1038/jid.2013.78. PubMed PMID: 23426133.
   PubMed Web of Science ®Google Scholar
• Bito T, Nishikawa R, Hatakeyama M, et al. Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis. Br J Dermatol. 2014;170(4):922–929. Epub 2013 Dec 18. doi:10.1111/bjd.12791. PubMed PMID: 24329764.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Maeda T, Tsuboi R, et al. Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: report of two cases. J Dermatol. 2013;40(5):389–392. Epub 2013 Feb 19. doi:10.1111/1346-8138.12093. PubMed PMID: 23414225.
   PubMed Web of Science ®Google Scholar
• Krintel SB, Grunert VP, Hetland ML, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology (Oxford). 2013;52(7):1245–1253. Epub 2013 Mar 6. doi:10.1093/rheumatology/ket017. PubMed PMID: 23459699.
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–608. doi:10.1056/NEJMoa020888.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Panes J, García V, et al. Long-term durability of infliximab treatment in Crohn’s disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol. 2011;45(2):113–118. Epub 2011 Jan 19. doi:10.1097/MCG.0b013e3181ebaef9. PubMed PMID: 21242747.
   PubMed Web of Science ®Google Scholar
• Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(9):1233–1238. Epub 2007 Mar 30. doi:10.1136/ard.2006.065995. PubMed PMID: 17392352; PubMed Central PMCID: PMCPMC2652128.
   PubMed Web of Science ®Google Scholar
• Menter MA, Cush JM. Successful treatment of pediatric psoriasis with infliximab. Pediatr Dermatol. 2004;21:87–88.
   PubMed Web of Science ®Google Scholar
• Farnsworth NN, George SJ, Hsu S. Successful use of infliximab following a failed course of etanercept in a pediatric patient. Dermatol Online J. 2005;11(3):11.
   PubMedGoogle Scholar
• Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin Cutan Med Surg. 2007;26(1):6–14. Epub 2007 Mar 14. doi:10.1016/j.sder.2006.12.002. PubMed PMID: 17349557.
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357(9271):1842–1847. Epub 2001 Jun 19. PubMed PMID: 11410193.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol. 2003;48(6):829–835. doi:10.1067/mjd.2003.307.
   PubMed Web of Science ®Google Scholar
• Luber AJ, Tsui CL, Heinecke GM, et al. Long-term durability and dose escalation patterns in infliximab therapy for psoriasis. J Am Acad Dermatol. 2014;70(3):525–532. Epub 2014 Jan 7. doi:10.1016/j.jaad.2013.10.059. PubMed PMID: 24388425.
   PubMed Web of Science ®Google Scholar
• Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol. 2007;56(1):e55–e79. Epub 2006 Dec 28. doi:10.1016/j.jaad.2006.07.019. PubMed PMID: 17190618.
   Google Scholar
• Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis. 2007;66(4):498–505. doi:10.1136/ard.2006.058339. PubMed PMID: PMC1856065.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–31.e15. Epub 2006 11 14. doi:10.1016/j.jaad.2006.07.017. PubMed PMID: 17097378.
   PubMed Web of Science ®Google Scholar
• Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol. 2013;168(6):1325–1334. Epub 2013 Apr 30. doi:10.1111/bjd.12404. PubMed PMID: 23621698.
   PubMed Web of Science ®Google Scholar
• Official Healthcare Professional Website for REMICADE® (infliximab). Official Healthcare Professional Website for REMICADE® (infliximab) [Internet]. 2016 [cited 2016 Feb 9]. Available from: http://www.remicade.com/hcp/
   Google Scholar
• Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64(4):671–681. Epub 2011 Mar 19. doi:10.1016/j.jaad.2010.03.009. PubMed PMID: 21414495.
   PubMed Web of Science ®Google Scholar
• Menting SP, Van Lumig PP, De Vries AC, et al. Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up. JAMA Dermatol. 2014;150(2):130–136. Epub 2013 Dec 20. doi:10.1001/jamadermatol.2013.8347. PubMed PMID: 24352354.
   PubMed Web of Science ®Google Scholar
• Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170(2):261–273. Epub 2013 Oct 15. doi:10.1111/bjd.12654. PubMed PMID: 24117166.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Van De Stadt LA, De Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis. 2013;72(1):104–109. Epub 2012 Jul 5. doi:10.1136/annrheumdis-2012-201445. PubMed PMID: 22759910.
   PubMed Web of Science ®Google Scholar
• Papp K, Crowley J, Ortonne JP, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol. 2011;164(2):434–441. Epub 2010 Nov 19. doi:10.1111/j.1365-2133.2010.10139.x. PubMed PMID: 21083543.
   PubMed Web of Science ®Google Scholar
• Lecluse LLA, Driessen RJB, Spuls PI, et al. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol. 2010;146(2):127–132. Epub 2010 Feb 17. doi:10.1001/archdermatol.2009.347. PubMed PMID: 20157022.
   PubMedGoogle Scholar
• Bartelds GM, Krieckaert CLM, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. Jama. 2011;305(14):1460–1468. Epub 2011 Apr 14. doi:10.1001/jama.2011.406. PubMed PMID: 21486979.
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 71. 2012. p. 1914–1915.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598–606. Epub 2006 Oct 3. doi:10.1016/j.jaad.2006.05.027. PubMed PMID: 17010738.
   PubMed Web of Science ®Google Scholar
• Bagel J. Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis. J Drugs Dermatol. 2011;10(4):366–371. Epub 2011 Apr 2. PubMed PMID: 21455546.
   PubMed Web of Science ®Google Scholar
• Papp K, Marcoux D, Landells I, et al. Adalimumab long-term safety/efficacy results for pediatric patients with chronic plaque psoriasis from a phase 3, randomized study. J Am Acad Dermatol. 2016;74(5):AB209. doi:10.1016/j.jaad.2016.02.822.
   Google Scholar
• Menter A, Thaçi D, Papp KA, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73(3):410–9.e6. Epub 2015 Jul 21. doi:10.1016/j.jaad.2015.06.038. PubMed PMID: 26190240.
   PubMed Web of Science ®Google Scholar
• Papp KA, Strober B, Augustin M, et al. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11(10):1210–1217. Epub 2012 Nov 9. PubMed PMID: 23134986.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969. Epub 2015 May 15. doi:10.1001/jamadermatol.2015.0718. PubMed PMID: 25970800.
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370(13):1198–1208. doi:10.1056/NEJMoa1306801.
   PubMed Web of Science ®Google Scholar
• Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–297. Epub 2013 Oct 26. doi:10.2340/00015555-1719. PubMed PMID: 24158307.
   PubMed Web of Science ®Google Scholar
• Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011;63(4):877–883. Epub 2011 Apr 1. doi:10.1002/art.30209. PubMed PMID: 21452312.
   PubMed Web of Science ®Google Scholar
• Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol. 2005;124(6):1275–1283. Epub 2005 Jun 16. doi:10.1111/j.0022-202X.2005.23735.x. PubMed PMID: 15955104.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175(4):2721–2729. Epub 2005 Aug 6. PubMed PMID: 16081850.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol. 2009;124(5):1022-10.e1-395. Epub 2009 Nov 10. doi:10.1016/j.jaci.2009.08.046. PubMed PMID: 19895991; PubMed Central PMCID: PMCPMC2852188.
   PubMed Web of Science ®Google Scholar
• Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007;204(13):3183–3194. Epub 2007 Nov 28. doi:10.1084/jem.20071094. PubMed PMID: 18039949; PubMed Central PMCID: PMCPMC2150965.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–2022. Epub 2003 Nov 25. doi:10.1056/NEJMoa030409. PubMed PMID: 14627786.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Strober B, Gottlieb AB, et al. Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study. J Drugs Dermatol. 2010;9(8):928–937. Epub 2010 Aug 6. PubMed PMID: 20684143.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143(6):719–726. Epub 2007 Jun 20. doi:10.1001/archderm.143.6.719. PubMed PMID: 17576937.
   PubMed Web of Science ®Google Scholar
• Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006;367(9504):29–35. Epub 2006 Jan 10. doi:10.1016/s0140-6736(05)67763-x. PubMed PMID: 16399150.
   PubMed Web of Science ®Google Scholar
• Krueger G, Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol. 2004;140(2):218–225. Epub 2004 Feb 18. doi:10.1001/archderm.140.2.218. PubMed PMID: 14967799.
   PubMedGoogle Scholar
• Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241–251. Epub 2008 Jan 18. doi:10.1056/NEJMoa066886. PubMed PMID: 18199863.
   PubMed Web of Science ®Google Scholar
• Amgen. FDA accepts Amgen’s supplemental biologics license application for the expanded use of Enbrel® (Etanercept) to treat pediatric patients with chronic severe Plaque Psoriasis. Thousand Oaks (CA): Amgen; 2016.
   Google Scholar
• Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167(3):649–657. doi:10.1111/j.1365-2133.2012.11015.x. PubMed PMID: PMC3504074.
   PubMed Web of Science ®Google Scholar
• Park KK, Wu JJ, Koo J. A randomized, ‘head-to-head’ pilot study comparing the effects of etanercept monotherapy vs. etanercept and narrowband ultraviolet B (NB-UVB) phototherapy in obese psoriasis patients. J Eur Acad Dermatol Venereol. 2013;27(7):899–906. Epub 2012 Jun 19. doi:10.1111/j.1468-3083.2012.04611.x. PubMed PMID: 22702846.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–1265. Epub 2004 5 6. doi:10.1086/383317. PubMed PMID: 15127338.
   PubMed Web of Science ®Google Scholar
• Van Dartel SA, Fransen J, Kievit W, et al. Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch rheumatoid arthritis monitoring (DREAM) registry. Ann Rheum Dis. 2013;72(6):895–900. Epub 2012 Aug 14. doi:10.1136/annrheumdis-2012-201338. PubMed PMID: 22887849.
   PubMed Web of Science ®Google Scholar
• Bourne T, Fossati G, Nesbitt A. A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs. 2008;22(5):331–337. Epub 2008 Sep 10. PubMed PMID: 18778114.
   PubMed Web of Science ®Google Scholar
• Reich K, Ortonne J-P, Gottlieb AB, et al. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab’ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. Br J Dermatol. 2012;167(1):180–190. Epub 2012 Mar 15. doi:10.1111/j.1365-2133.2012.10941.x. PubMed PMID: 22413944.
   PubMed Web of Science ®Google Scholar
• Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–1332. Epub 2007 Jul 20. doi:10.1002/ibd.20225. PubMed PMID: 17636564.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976–986. Epub 2009 Apr 1. doi:10.1002/art.24403. PubMed PMID: 19333944.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Van Der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504–2517. Epub 2012 Mar 2. doi:10.1002/art.34436. PubMed PMID: 22378566.
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Gottlieb AB. Ustekinumab for psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2012;89:86–89. Epub 2012 Jul 4. doi:10.3899/jrheum.120253. PubMed PMID: 22751602.
   PubMedGoogle Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665–1674. Epub 2008 50. doi:10.1016/s0140-6736(08)60725-4. PubMed PMID: 18486739.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675–1684. Epub 2008 May 20. doi:10.1016/s0140-6736(08)60726-6. PubMed PMID: 18486740.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Strober BE, Van De Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–128. Epub 2010 Jan 15. doi:10.1056/NEJMoa0810652. PubMed PMID: 20071701.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2004;51(4):534–542. Epub 2004 Sep 25. doi:10.1016/j.jaad.2004.02.021. PubMed PMID: 15389187.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115. doi:10.1016/j.jaad.2007.09.010.
   PubMed Web of Science ®Google Scholar
• Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168(4):844–854. Epub 2013Jan 11. doi:10.1111/bjd.12214. PubMed PMID: 23301632.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. Epub 2014 Jul 10. doi:10.1056/NEJMoa1314258. PubMed PMID: 25007392.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. Epub 2015 Jun 21. doi:10.1016/j.jaad.2015.05.013. PubMed PMID: 26092291.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. Epub 2015 Jun 15. doi:10.1016/s0140-6736(15)60125-8. PubMed PMID: 26072109.
   PubMed Web of Science ®Google Scholar
• Landells I, Marano C, Hsu M-C, et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol. 2015;73(4):594–603. Epub 2015 Aug 12. doi:10.1016/j.jaad.2015.07.002. PubMed PMID: 26259989.
   PubMed Web of Science ®Google Scholar
• Döffinger R, Dupuis S, Picard C, et al. Inherited disorders of IL-12- and IFNgamma-mediated immunity: a molecular genetics update. Mol Immunol. 2002;38(12–13):903–909. Epub 2002 May 16. PubMed PMID: 12009568.
   PubMed Web of Science ®Google Scholar
• Lehmann J, Bellmann S, Werner C, et al. IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis. J Immunol. 2001;167(9):5304–5315. Epub 2001 Oct 24. PubMed PMID: 11673546.
   PubMed Web of Science ®Google Scholar
• Gopal R, Lin Y, Obermajer N, et al. IL-23-dependent IL-17 drives Th1-cell responses following Mycobacterium bovis BCG vaccination. Eur J Immunol. 2012;42(2):364–373. Epub 2011 Nov 22. doi:10.1002/eji.201141569. PubMed PMID: 22101830; PubMed Central PMCID: PMCPMC3490408.
   PubMed Web of Science ®Google Scholar
• Paul C, Puig L, Kragballe K, et al. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Br J Dermatol. 2014;170(2):425–434. Epub 2013 Oct 15. doi:10.1111/bjd.12646. PubMed PMID: 24116959.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13(12):1441–1448. Epub 2015 Jan 22. PubMed PMID: 25607786.
   PubMed Web of Science ®Google Scholar
• Stamell EF, Kutner A, Viola K, et al. Ustekinumab associated with flares of psoriatic arthritis. JAMA Dermatol. 2013;149(12):1410–1413. Epub 2013 Oct 18. doi:10.1001/jamadermatol.2013.5728. PubMed PMID: 24132520.
   PubMed Web of Science ®Google Scholar
• Gratton D, Szapary P, Goyal K, et al. Reversible posterior leukoencephalopathy syndrome in a patient treated with ustekinumab: case report and review of the literature. Arch Dermatol. 2011;147(10):1197–1202. Epub 2011 Jun 18. doi:10.1001/archdermatol.2011.161. PubMed PMID: 21680761.
   PubMed Web of Science ®Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. Epub 2010 Oct 12. doi:10.1126/scitranslmed.3001107. PubMed PMID: 20926833.
   PubMed Web of Science ®Google Scholar
• Thaçi D, Humeniuk J, Frambach Y, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777–787. Epub 2015 Apr 1. doi:10.1111/bjd.13814. PubMed PMID: 25823958.
   PubMed Web of Science ®Google Scholar
• Van De Kerkhof PCM, Griffiths CEM, Reich K, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83-98.e4. Epub 2016 May 18. doi:10.1016/j.jaad.2016.03.024. PubMed PMID: 27180926.
   PubMed Web of Science ®Google Scholar
• Tlustochowicz W, Rahman P, Seriolo B, et al. Efficacy and safety of subcutaneous and intravenous loading dose regimens of secukinumab in patients with active rheumatoid arthritis: results from a randomized phase II study. J Rheumatol. 2016;43:495–503. Epub 2016 Feb 3. doi:10.3899/jrheum.150117. PubMed PMID: 26834211.
   PubMed Web of Science ®Google Scholar
• Letko E, Yeh S, Foster CS, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939–948. Epub 2015 Feb 2. doi:10.1016/j.ophtha.2014.12.033. PubMed PMID: 25638011.
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. Epub 2012 May 19. doi:10.1136/gutjnl-2011-301668. PubMed PMID: 22595313.
   PubMed Web of Science ®Google Scholar
• Gordon KB Ixekizumab for treatment of moderate-to-severe plaque psoriasis: 60-week results from a double-blind phase 3 induction and randomized withdrawal study (UNCOVER-1). 73rd Annual Meeting of the American Academy of Dermatology; 2015 Mar 20; San Francisco.
   Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–1189. Epub 2012 Mar 30. doi:10.1056/NEJMoa1109017. PubMed PMID: 22455412.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. Epub 2015 Oct 1. doi:10.1056/NEJMoa1503824. PubMed PMID: 26422722.
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase 3, randomised, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016. Epub 2016 Feb 26. doi:10.1111/bjd.14493. PubMed PMID: 26914406.
   Web of Science ®Google Scholar
• Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015;173(4):930–939. Epub 2015 Jun 5. doi:10.1111/bjd.13932. PubMed PMID: 26042589.
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–24.e7. Epub 2015 Mar 15. doi:10.1016/j.jaci.2015.01.018. PubMed PMID: 25769911.
   PubMed Web of Science ®Google Scholar
• Sofen H, Smith S, Matheson RT, et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014;133(4):1032–1040. Epub 2014 Apr 1. doi:10.1016/j.jaci.2014.01.025. PubMed PMID: 24679469.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med. 2015;373(2):136–144. Epub 2015 Jul 15. doi:10.1056/NEJMoa1501646. PubMed PMID: 26154787.
   PubMed Web of Science ®Google Scholar
• Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29(4):645–648. Epub 2014 Nov 6. doi:10.1111/jdv.12817. PubMed PMID: 25370811.
   PubMed Web of Science ®Google Scholar
• Strober BE, Bissonnette R, Fiorentino D, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). J Am Acad Dermatol. 2016;74:851-861.e4. Epub 2016 Feb 9. doi:10.1016/j.jaad.2015.12.017. PubMed PMID: 26853180.
   PubMed Web of Science ®Google Scholar
• Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol. 2006;54(Suppl 4):S171–S181.Epub 2006 Feb 21. doi:10.1016/j.jaad.2005.10.029. PubMed PMID: 16488339.
   Google Scholar
• Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171(1):137–147. Epub 2014 Apr 2. doi:10.1111/bjd.13013. PubMed PMID: 24684204; PubMed Central PMCID: PMCPMC4232924.
   PubMed Web of Science ®Google Scholar
• Militello G, Xia A, Stevens SR, et al. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55(3):517–519. Epub 2006 Aug 16. doi:10.1016/j.jaad.2006.02.010. PubMed PMID: 16908365.
   PubMed Web of Science ®Google Scholar
• Radtke MA, Augustin M. Biosimilars in psoriasis: what can we expect? J Dtsch Dermatol Ges. 2014;12(4):306–312. Epub 2014 Apr 5. doi:10.1111/ddg.12294. PubMed PMID: 24698590.
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 29. 2011. p. 310–312.
   PubMed Web of Science ®Google Scholar
• Tebbey PW, Varga A, Naill M, et al. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). MAbs. 2015;7(5):805–811. Epub 2015 Aug 1. doi:10.1080/19420862.2015.1073429. PubMed PMID: 26230301; PubMed Central PMCID: PMCPMC4622832.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612. Epub 2013 May 21. doi:10.1136/annrheumdis-2012-203091. PubMed PMID: 23687259; PubMed Central PMCID: PMCPMC3786643.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620. Epub 2013 May 21. doi:10.1136/annrheumdis-2012-203090. PubMed PMID: 23687260; PubMed Central PMCID: PMCPMC3786641.
   PubMed Web of Science ®Google Scholar
• Tichy M, Kopova R, Sternbersky J. First experience with therapy of severe forms of psoriasis with biosimilar infliximab. J Eur Acad Dermatol Venereol. 2016;30(3):491–493. Epub 2014 Nov 25. doi:10.1111/jdv.12876. PubMed PMID: 25418715.
   PubMed Web of Science ®Google Scholar
• Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16(9):443. Epub 2014 Jul 17. doi:10.1007/s11926-014-0443-6. PubMed PMID: 25027606.
   PubMed Web of Science ®Google Scholar
• Kofoed K, Skov L, Zachariae C. New drugs and treatment targets in psoriasis. Acta Derm Venereol. 2015;95(2):133–139. Epub 2014 Aug 12. doi:10.2340/00015555-1931. PubMed PMID: 25111317.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Van De Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386(9993):552–561. Epub 2015 Jun 9. doi:10.1016/s0140-6736(14)62113-9. PubMed PMID: 26051365.
   PubMed Web of Science ®Google Scholar
• Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–145. doi:10.1111/bjd.12266. PubMed PMID: PMC3761190.
   PubMed Web of Science ®Google Scholar
• Barosi G, Rosti V. Novel strategies for patients with chronic myeloproliferative disorders. Curr Opin Hematol. 2009;16(2):129–134. Epub 2009 May 27. doi:10.1097/MOH.0b013e3283257a9e. PubMed PMID: 19468275.
   PubMed Web of Science ®Google Scholar
• Punwani N, Scherle P, Flores R, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol. 2012;67(4):658–664. Epub 2012 Jan 28. doi:10.1016/j.jaad.2011.12.018. PubMed PMID: 22281165.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842–855. Epub 2010 Jan 7. doi:10.1111/j.1476-5381.2009.00559.x. PubMed PMID: 20050849; PubMed Central PMCID: PMCPMC2829210.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49. Epub 2015 Jun 20. doi:10.1016/j.jaad.2015.03.049. PubMed PMID: 26089047.
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Liang BT, et al. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17(7–8):359–366. Epub 2011 Oct 29. doi:10.1016/j.drudis.2011.10.007. PubMed PMID: 22033198; PubMed Central PMCID: PMCPMC3289754.
   PubMed Web of Science ®Google Scholar
• David M, Akerman L, Ziv M, et al. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. J Eur Acad Dermatol Venereol. 2012;26(3):361–367. Epub 2011 Apr 21. doi:10.1111/j.1468-3083.2011.04078.x. PubMed PMID: 21504485.
   PubMed Web of Science ®Google Scholar
• Skepner J, Ramesh R, Trocha M, et al. Pharmacologic inhibition of RORγt regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo. J Immunol. 2014;192(6):2564–2575. Epub 2014 Feb 12. doi:10.4049/jimmunol.1302190. PubMed PMID: 24516202.
   PubMed Web of Science ®Google Scholar
• Autoimmune disease - Vitae Pharmaceuticals [Internet]. 2016. [cited 2016 Feb 10]. Available from: http://vitaepharma.com/pipeline/autoimmune-diseases/
   Google Scholar